Bruker (NASDAQ:BRKR)‘s stock had its “equal weight” rating reissued by Morgan Stanley in a research note issued to investors on Thursday. They presently have a $35.00 target price on the medical research company’s stock. Morgan Stanley’s price objective suggests a potential upside of 1.07% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on BRKR. BidaskClub raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Goldman Sachs Group reaffirmed a “sell” rating and issued a $24.00 target price on shares of Bruker in a report on Tuesday, September 26th. J P Morgan Chase & Co raised shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price on the stock in a report on Friday, November 3rd. Bank of America raised shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a report on Friday, November 3rd. Finally, Cowen reaffirmed a “hold” rating and issued a $29.00 target price on shares of Bruker in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.08.

Shares of Bruker (BRKR) opened at $34.63 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.60 and a current ratio of 2.60. Bruker has a 52-week low of $21.03 and a 52-week high of $36.53. The company has a market cap of $5,500.00, a PE ratio of 28.97, a price-to-earnings-growth ratio of 2.87 and a beta of 1.11.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. During the same period in the previous year, the firm posted $0.32 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. sell-side analysts anticipate that Bruker will post 1.19 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Acrospire Investment Management LLC grew its stake in Bruker by 496.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after buying an additional 3,185 shares during the last quarter. SG Americas Securities LLC acquired a new position in Bruker in the 2nd quarter valued at about $111,000. Zions Bancorporation acquired a new position in Bruker in the 3rd quarter valued at about $119,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Bruker by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after buying an additional 467 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares during the last quarter. Institutional investors and hedge funds own 65.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/12/16/bruker-brkr-rating-reiterated-by-morgan-stanley.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.